{"product_id":"ntla-swot-analysis","title":"(NTLA) Intellia Therapeutics, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Credibility Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Intellia Therapeutics, Inc. SWOT Analysis gives a concise, company-specific view of strengths, weaknesses, opportunities, and threats for strategy, investing, or research; the content on this page is a genuine preview of the actual report so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use SWOT analysis for immediate use in presentations or due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRISPR\/Cas9 core platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is built on a single CRISPR\/Cas9 base, which keeps its science focused and repeatable across programs. Its lead in vivo asset, NTLA-2001, has shown durable transthyretin knockdown of about 90% in clinical testing, while NTLA-2002 produced strong hereditary angioedema reductions. That shared platform can speed new targets and cut development duplication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 lead programs in Phase 1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. has 2 lead programs in Phase 1: NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. These clinical-stage assets give real human-data readouts, so investors can judge safety and early efficacy instead of waiting on preclinical signals. They also create nearer-term catalysts, with 2 ongoing programs that can move on first-in-human data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad liver-focused pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. has a broad liver-editing slate across at least 3 serious rare diseases: hemophilia A and B, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. That range lowers single-program risk and supports more shots on goal in large unmet-need markets. A liver-first delivery model also helps keep dosing and manufacturing more consistent across programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEx vivo AML candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNTLA-5001 gives Intellia Therapeutics, Inc. an ex vivo acute myeloid leukemia program, widening its pipeline beyond liver-directed in vivo editing and into oncology. That matters because AML still has poor outcomes, with a 5-year relative survival of about 32.9% in U.S. data, so even a single credible program can broaden both science and market reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEx vivo AML expands pipeline scope\u003c\/li\u003e\n\u003cli\u003eMoves beyond liver-only editing\u003c\/li\u003e\n\u003cli\u003eAdds oncology exposure\u003c\/li\u003e\n\u003cli\u003eTargets a high-need cancer area\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMajor collaboration network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia’s major collaboration network is a real strength: it spans four named partners, Novartis, Regeneron, Ospedale San Raffaele, and SparingVision. That gives Intellia outside scientific validation and extra development capacity while widening its reach across liver, oncology, immunology, and eye disease work.\u003c\/p\u003e\n\u003cp\u003eThese ties also lower execution risk because partners share know-how, data, and clinical support. For a gene-editing company with no commercial revenue from approved products as of 2025, that kind of backing matters a lot.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour major collaboration partners\u003c\/li\u003e\n\u003cli\u003eBroader disease-area access\u003c\/li\u003e\n\u003cli\u003eExternal scientific validation\u003c\/li\u003e\n\u003cli\u003eShared development support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s CRISPR Pipeline Shows Durable Phase 1 Promise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. has 2 lead Phase 1 programs, NTLA-2001 and NTLA-2002, with durable human data: about 90% transthyretin knockdown and strong hereditary angioedema reductions. Its single CRISPR\/Cas9 platform supports 3+ liver-editing programs and one ex vivo AML asset, broadening shots on goal. Four major partners add scientific validation and shared development support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead programs\u003c\/td\u003e\n\u003ctd\u003e2 Phase 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2001\u003c\/td\u003e\n\u003ctd\u003e~90% knockdown\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Intellia Therapeutics, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick SWOT snapshot for Intellia Therapeutics, helping teams spot risks and opportunities fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking each Intellia Therapeutics claim to primary industry reports, peer-reviewed studies, SEC filings, and market datasets for fast, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. still has no approved product, so it remains a development-stage biotech. That leaves the business dependent on clinical data and FDA or EMA decisions rather than commercial sales. Until one therapy reaches the market, execution risk stays high and value can swing sharply on trial results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy reliance on clinical milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. still leans on early clinical wins, with lead programs like NTLA-2001 and NTLA-2002 in Phase 1\/2 stages. Small cohorts often mean only about 10 to 30 patients, so one data update can be hard to read. A setback in any lead asset can quickly damage sentiment and valuation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital-intensive R\u0026amp;D model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia’s genome-editing pipeline demands heavy, ongoing R\u0026amp;D spend, with annual research costs in the hundreds of millions plus trial, manufacturing, and regulatory work. It must fund several programs at once, so cash burn stays high before any product sales arrive. That can strain liquidity and force reliance on financing or partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConcentration in rare disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. leans heavily on rare-disease programs such as hereditary angioedema, ATTR amyloidosis, and alpha-1 antitrypsin deficiency. These patient pools are scientifically compelling but small, so even successful launches can take longer to build meaningful sales than larger, broader markets.\u003c\/p\u003e\n\u003cp\u003eThat makes revenue scaling slower and more uneven, especially while Intellia is still funding late-stage R\u0026amp;D ahead of commercialization. In rare disease, high unmet need helps pricing, but the total addressable market stays limited by low prevalence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall patient pools cap peak sales\u003c\/li\u003e\n\u003cli\u003eRevenue ramps slower than larger indications\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend stays high before launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform dependence on CRISPR\/Cas9\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is heavily tied to CRISPR\/Cas9, so the brand and pipeline both depend on one editing system. If a safety or efficacy problem shows up in that platform, it can affect multiple programs at once, not just one trial. That creates portfolio-wide risk and can pressure valuation fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne core platform drives the pipeline\u003c\/li\u003e\n\u003cli\u003eOne flaw can hit many programs\u003c\/li\u003e\n\u003cli\u003eRisk spreads across the whole portfolio\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSo the weakness is not just technical; it is structural.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s Pipeline Faces High Binary Risk and Platform Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. remains exposed to binary trial risk: it has no approved product, and lead programs NTLA-2001 and NTLA-2002 are still in Phase 1\/2. Its rare-disease focus also limits scale, while CRISPR\/Cas9 concentration means one platform issue can hit the whole pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo product\u003c\/td\u003e\n\u003ctd\u003e0 approved therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead programs\u003c\/td\u003e\n\u003ctd\u003e2 in Phase 1\/2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform risk\u003c\/td\u003e\n\u003ctd\u003e1 core editing system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eIntellia Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, covering Intellia Therapeutics' strengths, weaknesses, opportunities, and threats with actionable insights and data-driven commentary. Purchase unlocks the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-2001 value creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2001 can create value if its Phase 1 data keeps showing deep, durable TTR lowering in transthyretin amyloidosis, where even one-dose editing could be a step change versus chronic therapy. Strong readouts would boost confidence in in vivo gene editing and help broaden adoption of Intellia Therapeutics, Inc.'s platform, especially after the company held about $1.0 billion in cash and investments in 2025 to fund late-stage work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-2002 expansion potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2002 targets hereditary angioedema, a rare disease affecting about 1 in 50,000 people, so even modest uptake can matter. In Intellia Therapeutics, Inc. Phase 2 data, attack rates fell by about 93% at 16 weeks, which supports a strong unmet-need case. If later studies confirm durable dosing, it could also validate repeated in vivo editing in patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeeper liver-therapy expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. is building a deeper liver-therapy franchise with 3 key programs in hemophilia A and B, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. That widens the addressable market beyond one disease and lets the Company reuse the same liver-targeting and gene-editing platform across multiple shots on goal. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology and cell-therapy entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. can widen its long-run growth base if NTLA-5001 moves successfully into acute myeloid leukemia, while its engineered cell-therapy work in oncology and autoimmune disease opens lanes beyond liver editing. AML alone accounts for about 1.3% of all new U.S. cancer cases, but it is a high-need market with limited durable options. These programs give Intellia Therapeutics, Inc. a shot at multiple shots on goal, not just liver disease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNTLA-5001 adds AML exposure.\u003c\/li\u003e\n\u003cli\u003eCell therapy expands beyond liver disease.\u003c\/li\u003e\n\u003cli\u003eAutoimmune and oncology widen the runway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered ocular development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s alliance with SparingVision gives it a way to push genomic medicines into ocular disease without bearing the full cost and risk alone. Partnered programs can widen the addressable market beyond the liver-focused core, while sharing R\u0026amp;D burden and speeding learning in a second modality. This also adds pipeline balance if one area slows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShares ocular R\u0026amp;D risk.\u003c\/li\u003e\n\u003cli\u003eExpands beyond liver focus.\u003c\/li\u003e\n\u003cli\u003eBroadens indication reach.\u003c\/li\u003e\n\u003cli\u003eAdds pipeline diversification.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s Deep-Edit Pipeline Could Keep Delivering in 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. can still gain from NTLA-2001 and NTLA-2002 if 2026 data keeps showing deep, durable editing in rare diseases, where one-time treatment can beat chronic dosing. The Company also has about $1.0 billion in cash and investments in 2025, giving it room to push late-stage work. Its liver, oncology, and autoimmune pipeline adds more shots on goal.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2002\u003c\/td\u003e\n\u003ctd\u003e~93% attack-rate cut at 16 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003e~$1.0B cash and investments, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline breadth\u003c\/td\u003e\n\u003ctd\u003eLiver, AML, ocular, autoimmune\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial failure is a real risk for Intellia Therapeutics, Inc. because Phase 1 programs can miss on safety or efficacy, and its lead in vivo CRISPR assets still depend on later readouts. A negative data drop can cut valuation fast, since biotech shares often reprice on a single trial result. It can also make funding harder and more expensive if investors lose confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory scrutiny for genome editing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCRISPR-based therapies face heavy scrutiny because they rewrite DNA, so Intellia Therapeutics, Inc. must prove durable safety as well as efficacy. The FDA can require up to 15 years of long-term follow-up for gene therapy products, which raises trial costs and slows data readouts. That can delay approvals, stretch R\u0026amp;D spending, and push revenue far into the future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from gene-editing peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe genome-editing arena is crowded, with peers like CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, and Verve racing for the same partners and capital. Rival programs can pull investor attention away fast, especially when they show clearer clinical progress or larger balance sheets. Intellia Therapeutics, Inc. has to keep proving its edge in in vivo editing, or it risks losing share of a market still in early clinical innings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntellectual property disputes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. faces high IP risk because CRISPR\/Cas9 is built on dense patent estates and layered licenses, so even one challenge can lift legal costs and slow programs. Patent fights in gene editing can also restrict freedom to operate and force royalty deals that hurt margins. This is a sector-wide threat that stays live through 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeavy patent thickets raise licensing costs\u003c\/li\u003e\n\u003cli\u003eIP suits can delay clinical and deal plans\u003c\/li\u003e\n\u003cli\u003eRoyalty pressure can cut future margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFinancing and market volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. remains exposed to financing risk because it is still pre-commercial and funds most R\u0026amp;D through cash reserves, capital markets, and partner deals. As of its last reported quarter, the company had about $1.0 billion in cash, cash equivalents, and marketable securities, but rising rates and weak biotech sentiment can still raise dilution risk and tighten access to new funding, which can slow pipeline work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-commercial, so funding depends on markets\u003c\/li\u003e\n\u003cli\u003eHigher rates can lift financing costs\u003c\/li\u003e\n\u003cli\u003eWeak biotech sentiment can limit capital access\u003c\/li\u003e\n\u003cli\u003eSlower funding can delay pipeline development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s Big Risks: Trials, FDA Delays, and Funding Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. still faces key threats: trial setbacks, long FDA follow-up rules, strong CRISPR competition, and patent risk. Its pre-commercial model also leaves it exposed to funding swings; it ended the last reported quarter with about $1.0 billion in cash, cash equivalents, and marketable securities, but that may not cover delays or weak biotech markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding risk\u003c\/td\u003e\n\u003ctd\u003e~$1.0B cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory delay\u003c\/td\u003e\n\u003ctd\u003eUp to 15-year follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical risk\u003c\/td\u003e\n\u003ctd\u003ePhase 1 readouts pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234770297097,"sku":"ntla-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ntla-swot-analysis.webp?v=1785726795","url":"https:\/\/dcfanalyst.com\/products\/ntla-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}